Anika Therapeutics (ANIK) Non-Current Deffered Revenue (2010 - 2016)
Anika Therapeutics (ANIK) posted quarterly Non-Current Deffered Revenue of $48000.0 for Q4 2016, down 27.27% year-over-year from $66000.0 in Q1 2016, and down 18.64% quarter-over-quarter from $59000.0 in Q3 2016.
Anika Therapeutics (ANIK) Non-Current Deffered Revenue (2010 - 2016) Analysis & Trends
Anika Therapeutics (ANIK) has reported Non-Current Deffered Revenue for 7 consecutive years, with $48000.0 the latest figure, recorded in Q4 2016.
- In Q4 2016, Non-Current Deffered Revenue fell 27.27% year-over-year to $48000.0; the TTM figure through Dec 2016 stood at $48000.0 (down 27.27% YoY), while the FY2016 annual figure was $48000.0, down 27.27% from the prior year.
- Non-Current Deffered Revenue slipped to $48000.0 in Q4 2016 per ANIK's latest filing, from $59000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $4.3 million in Q1 2012 and bottomed at $48000.0 in Q4 2016.
- Historically, Non-Current Deffered Revenue has averaged $1.1 million across 5 years, with a median of $79940.5 in 2015.
- Annual changes were most pronounced in 2014 — Non-Current Deffered Revenue tumbled 97.21% — and 2015, when it soared 30.74%.
- Anika Therapeutics' Non-Current Deffered Revenue stood at $2.2 million in 2012, then fell by 4.54% to $2.1 million in 2013, then slumped by 95.04% to $102000.0 in 2014, then tumbled by 35.29% to $66000.0 in 2015, then decreased by 27.27% to $48000.0 in 2016.
- Business Quant data shows ANIK's Non-Current Deffered Revenue at $48000.0 in Q4 2016, $59000.0 in Q3 2016, and $56000.0 in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Anika Therapeutics | 286.14 Mn | 247.73 Mn | 21.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 48,000.00 |
| Sep 30, 2016 | 59,000.00 |
| Jun 30, 2016 | 56,000.00 |
| Mar 31, 2016 | 63,000.00 |
| Dec 31, 2015 | 66,000.00 |
| Sep 30, 2015 | 73,964.00 |
| Jun 30, 2015 | 74,371.00 |
| Mar 31, 2015 | 85,510.00 |
| Dec 31, 2014 | 102,000.00 |
| Sep 30, 2014 | 56,573.00 |
| Jun 30, 2014 | 71,446.00 |
| Mar 31, 2014 | 72,367.00 |
| Dec 31, 2013 | 2.05 Mn |
| Sep 30, 2013 | 2.03 Mn |
| Jun 30, 2013 | 2.07 Mn |
| Mar 31, 2013 | 2.11 Mn |
| Dec 31, 2012 | 2.15 Mn |
| Sep 30, 2012 | 2.87 Mn |
| Jun 30, 2012 | 3.59 Mn |
| Mar 31, 2012 | 4.30 Mn |